LAG3 and malignant colon neoplasm: Subsequent studies have demonstrated impressive response rates to neoadjuvant PD-1 and CTLA-4 blockade (NICHE-2) (101), and PD-1 and LAG-3 blockade (NICHE-3) (102) in 113 and 59 patients with dMMR locally-advanced colonic cancer respectively.